17.11.2016 | Typ-2-Diabetes | Journal Club
Kombinationstherapie zweier Inkretinmimetika bei Typ-2-Diabetes
Erschienen in: Die Diabetologie | Ausgabe 8/2016
Einloggen, um Zugang zu erhaltenAuszug
Nauck MA, Kahle M, Baranov O et al (2016) A randomized controlled trial of adding the DPP-4 inhibitor sitagliptin to ongoing therapy with liraglutide (GLP-1 receptor agonist): Increases in intact GLP-1 and GIP, but no change in insulin, glucagon or plasma glucose following a mixed meal in patients with type 2 diabetes. Diabetes Obes Metab 6. doi: 10.1111/dom.12802. (Epub ahead of print) …Anzeige